(Q30381447)

21 June 2017

1 reference

title

HIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development. (English)

1 reference

21 June 2017

1 reference

Giovanni Paniccia

8

0 references

Stefania Bellino

Stefania Bellino

3

0 references

Flavia Ferrantelli

Flavia Ferrantelli

11

0 references

Cecilia Sgadari

Cecilia Sgadari

7

0 references

Fabrizio Ensoli

Fabrizio Ensoli

13

0 references

Antonella Caputo

Antonella Caputo

1

0 references

Riccardo Gavioli

Riccardo Gavioli

2

0 references

Paolo Monini

Paolo Monini

12

0 references

Barbara Ensoli

Barbara Ensoli

14

0 references

author name string

Olimpia Longo

4

1 reference

21 June 2017

Antonella Tripiciano

5

1 reference

21 June 2017

Vittorio Francavilla

6

1 reference

21 June 2017

Fausto Titti

9

1 reference

21 June 2017

Aurelio Cafaro

10

1 reference

21 June 2017

publication date

1 January 2009

1 reference

International Reviews of Immunology

21 June 2017

published in

1 reference

21 June 2017

volume

28

1 reference

21 June 2017

issue

5

1 reference

21 June 2017

page(s)

285-334

1 reference

HIV/AIDS vaccines: a need for new concepts?

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Problems and emerging approaches in HIV/AIDS vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

HIV vaccine development: lessons from the past and promise for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Protective immunity to SIV challenge elicited by vaccination of macaques with multigenic DNA vaccines producing virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Boosting of SIV-specific immune responses in rhesus macaques by repeated administration of Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinants

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Progress and obstacles in the development of an AIDS vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

21 January 2018

HIV/AIDS vaccines: 2007.

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Identifying epitopes of HIV-1 that induce protective antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

A role for carbohydrates in immune evasion in AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

HIV vaccine design and the neutralizing antibody problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

21 January 2018

HIV vaccines 1983-2003.

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

The causes and consequences of HIV evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

HIV genetic diversity: biological and public health consequences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Long-lasting protection by live attenuated simian immunodeficiency virus in cynomolgus monkeys: no detection of reactivation after stimulation with a recall antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies--implications for acquired immunodeficiency syndrome vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Neutralizing antibodies against HIV -- back in the major leagues?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Breast milk and HIV-1: vector of transmission or vehicle of protection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

The search for the CD8+ cell anti-HIV factor (CAF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Protection from HIV/AIDS: the importance of innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Antibody protection: passive immunization of neonates against oral AIDS virus challenge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Therapeutic potential of neutralizing antibodies in the treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

DNA vaccination with the human immunodeficiency virus type 1 SF162DeltaV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Antibody vs. HIV in a clash of evolutionary titans

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Development of V2-deleted trimeric envelope vaccine candidates from human immunodeficiency virus type 1 (HIV-1) subtypes B and C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Comparative evaluation of trimeric envelope glycoproteins derived from subtype C and B HIV-1 R5 isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Purification, Characterization, and Immunogenicity of a Soluble Trimeric Envelope Protein Containing a Partial Deletion of the V2 Loop Derived from SF162, an R5-Tropic Human Immunodeficiency Virus Type 1 Isolate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Dynamics of acute and memory mucosal and systemic immune responses against HIV-1 envelope following immunizations through single or combinations of mucosal and systemic routes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Broad cross-clade T-cell responses to gag in individuals infected with human immunodeficiency virus type 1 non-B clades (A to G): importance of HLA anchor residue conservation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Recent advances in the development of HIV-1 Tat-based vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Rational vaccine strategies against AIDS: background and rationale

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Nonstructural HIV proteins as targets for prophylactic or therapeutic vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

CD8+ T-cells: are they sufficient to prevent, contain or eradicate HIV-1 infection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Antiviral CD8+ T cells in the genital tract control viral replication and delay progression to AIDS after vaginal SIV challenge in rhesus macaques immunized with virulence attenuated SHIV 89.6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Gag-specific cytotoxic T-lymphocyte-based control of primary simian immunodeficiency virus replication in a vaccine trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Macaques vaccinated with live-attenuated SIV control replication of heterologous virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Human immunodeficiency virus interactions with CD8+ T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Dynamics of immune escape during HIV/SIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Tonsilar NK cells restrict B cell transformation by the Epstein-Barr virus via IFN-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Failure of the Merck HIV vaccine: an uncertain step forward.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Relevance of studying T cell responses in SIV-infected rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

CD8+ T cell efficacy in vaccination and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Correlates of immune protection and the development of a human immunodeficiency virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Not just sheer luck! Immune correlates of protection against HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Building collaborative networks for HIV/AIDS vaccine development: the AVIP experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Current advances and challenges in HIV-1 vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

HIV subtypes and recombination strains--strategies for induction of immune responses in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response that appears prevalent in the asymptomatic stage of infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

HIV-1 tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

HIV-1 Tat raises an adjuvant-free humoral immune response controlled by its core region and its ability to form cysteine-mediated oligomers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Angiogenic effects of extracellular human immunodeficiency virus type 1 Tat protein and its role in the pathogenesis of AIDS-associated Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

HIV pathogenesis: knowledge gained after two decades of research

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

HIV-1 Tat and AIDS-associated cancer: targeting the cellular anti-cancer barrier?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

HIV tat and neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Extracellular HIV type 1 Tat protein induces CD69 expression through NF-kappaB activation: possible correlation with cell surface Tat-binding proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Role for human immunodeficiency virus type 1 Tat protein in suppression of viral reverse transcriptase activity during late stages of viral replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

HIV-1 Tat alters normal organization of neurons and astrocytes in primary rodent brain cell cultures: RGD sequence dependence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

NF-kappaB-dependent control of HIV-1 transcription by the second coding exon of Tat in T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

An in vivo replication-important function in the second coding exon of Tat is constrained against mutation despite cytotoxic T lymphocyte selection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Second exon of Tat of HIV-2 is required for optimal trans-activation of HIV-1 and HIV-2 LTRs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

On the role of the second coding exon of the HIV-1 Tat protein in virus replication and MHC class I downregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Paracrine activation of the HIV-1 LTR promoter by the viral Tat protein is mechanistically similar to trans-activation within a cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Tat mutations in an African cohort that do not prevent transactivation but change its immunogenic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Natural antibodies to HIV-tat epitopes and expression of HIV-1 genes in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Antibody to HIV-1 Tat protein inhibits the replication of virus in culture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

DNA vaccination in mice using HIV-1 nef, rev and tat genes in self-replicating pBN-vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

A monoclonal antibody defines a novel HIV type 1 Tat domain involved in trans-cellular trans-activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Epitopes for natural antibodies of human immunodeficiency virus (HIV)-negative (normal) and HIV-positive sera are coincident with two key functional sequences of HIV Tat protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Tat-neutralizing versus Tat-protecting antibodies in rhesus macaques vaccinated with Tat peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Antibodies against a multiple-peptide conjugate comprising chemically modified human immunodeficiency virus type-1 functional Tat peptides inhibit infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Delivery of the HIV-1 Tat protein to dendritic cells by the CyaA vector induces specific Th1 responses and high affinity neutralizing antibodies in non human primates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Design and characterization of an HIV-1 Tat mutant: inactivation of viral and cellular functions but not antigenicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Important B-cell epitopes for neutralization of human immunodeficiency virus type 1 Tat in serum samples of humans and different animal species immunized with Tat protein or peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Fruit-specific expression of the human immunodeficiency virus type 1 tat gene in tomato plants and its immunogenic potential in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Tat-neutralizing antibodies in vaccinated macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Reservoir cells no longer detectable after a heterologous SHIV challenge with the synthetic HIV-1 Tat Oyi vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Two B cell epitopes of HIV-1 Tat protein have limited antigenic polymorphism in geographically diverse HIV-1 strains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

DNA prime and protein boost immunization with innovative polymeric cationic core-shell nanoparticles elicits broad immune responses and strongly enhance cellular responses of HIV-1 tat DNA vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Immunoprevalence of the CD4+ T-cell response to HIV Tat and Vpr proteins is provided by clustered and disperse epitopes, respectively

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Mucosal delivery of the human immunodeficiency virus-1 Tat protein in mice elicits systemic neutralizing antibodies, cytotoxic T lymphocytes and mucosal IgA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Tat HIV-1 primary and tertiary structures critical to immune response against non-homologous variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Recombinant human Fab antibody fragments to HIV-1 Rev and Tat regulatory proteins: direct selection from a combinatorial phage display library

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Homonuclear (1)H-NMR assignment and structural characterization of human immunodeficiency virus type 1 Tat Mal protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-secreting CD8+ T cells in primary HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

CTL responses to regulatory proteins Tat and Rev in HIV-1 B'/C virus-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Identification of human immunodeficiency virus type 1 subtype C Gag-, Tat-, Rev-, and Nef-specific elispot-based cytotoxic T-lymphocyte responses for AIDS vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Quantifying the uncertainty in forecasts of anthropogenic climate change

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Cytotoxic T-lymphocyte escape monitoring in simian immunodeficiency virus vaccine challenge studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Trans-activator gene of human T-lymphotropic virus type III (HTLV-III).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

HIV-1 subtypes: epidemiology and significance for HIV management

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Containment of infection in tat vaccinated monkeys after rechallenge with a higher dose of SHIV89.6P(cy243).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

cDNA cloning and sequencing reveal the major horse allergen Equ c1 to be a glycoprotein member of the lipocalin superfamily.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Full peptide synthesis, purification, and characterization of six Tat variants. Differences observed between HIV-1 isolates from Africa and other continents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Minimization of chronic plasma viremia in rhesus macaques immunized with synthetic HIV-1 Tat peptides and infected with a chimeric simian/human immunodeficiency virus (SHIV33).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Outcome of simian-human immunodeficiency virus strain 89.6p challenge following vaccination of rhesus macaques with human immunodeficiency virus Tat protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhe

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV(89.6P) infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Advantageous features of plant-based systems for the development of HIV vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Is there a role for plant-made vaccines in the prevention of HIV/AIDS?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Synthesis of an HIV-1 Tat transduction domain-rotavirus enterotoxin fusion protein in transgenic potato

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Clarification of how HIV-1 DNA and protein immunizations may be better used to obtain HIV-1-specific mucosal and systemic immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

DNA mucosal HIV vaccine in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Core-shell microspheres by dispersion polymerization as promising delivery systems for proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Novel biocompatible anionic polymeric microspheres for the delivery of the HIV-1 Tat protein for vaccine application

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Functional polymeric nano/microparticles for surface adsorption and delivery of protein and DNA vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Strong T cell type-1 immune responses to HIV-1 Tat (1-72) protein-coated nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Formulation of HIV-1 Tat and p24 antigens by PLA nanoparticles or MF59 impacts the breadth, but not the magnitude, of serum and faecal antibody responses in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Micellar-type complexes of tailor-made synthetic block copolymers containing the HIV-1 tat DNA for vaccine application

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Immunization with low doses of HIV-1 tat DNA delivered by novel cationic block copolymers induces CTL responses against Tat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

The cationic region from HIV tat enhances the cell-surface expression of epitope/MHC class I complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Tat-mediated delivery of heterologous proteins into cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Protein transduction: unrestricted delivery into all cells?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Enhanced induction of anti-tumor immunity in human and mouse by dendritic cells pulsed with recombinant TAT fused human survivin protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Dendritic cells transduced with TAT protein transduction domain-containing tyrosinase-related protein 2 vaccinate against murine melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Intracellular HIV-1 Tat protein represses constitutive LMP2 transcription increasing proteasome activity by interfering with the binding of IRF-1 to STAT1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

HIV Tat-mediated transcriptional regulation of proteasome protein cleavage specificity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Identification of new HIV-1 Gag-specific cytotoxic T lymphocyte responses in BALB/c mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

A Tat subunit vaccine confers protective immunity against the immune-modulating activity of the human immunodeficiency virus type-1 Tat protein in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Interactions of single and combined human immunodeficiency virus type 1 (HIV-1) DNA vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Functionally-inactive and immunogenic Tat, Rev and Nef DNA vaccines derived from sub-Saharan subtype C human immunodeficiency virus type 1 consensus sequences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Therapeutic immunization with Modified Vaccinia Virus Ankara (MVA) vaccines in SIV-infected rhesus monkeys undergoing antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Vaccination with Rev and Tat against AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

The advantage of early recognition of HIV-infected cells by cytotoxic T-lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Comparison of the efficacy of early versus late viral proteins in vaccination against SIV

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Evaluation in Rhesus Macaques of Tat and Rev-Targeted Immunization as a Preventive Vaccine against Mucosal Challenge with SHIV-BX08

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Maternal immune status influences HIV-specific immune responses in pups after DNA prime protein boost using mucosal adjuvant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Broad, high-magnitude and multifunctional CD4+ and CD8+ T-cell responses elicited by a DNA and modified vaccinia Ankara vaccine containing human immunodeficiency virus type 1 subtype C genes in baboons

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Design and preclinical evaluation of a multigene human immunodeficiency virus type 1 subtype C DNA vaccine for clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Comparative efficacy of subtype AE simian-human immunodeficiency virus priming and boosting vaccines in pigtail macaques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Chimaeric HIV-1 subtype C Gag molecules with large in-frame C-terminal polypeptide fusions form virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Design, construction, and characterization of a dual-promoter multigenic DNA vaccine directed against an HIV-1 subtype C/B' recombinant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Induction of long-lasting multi-specific CD8+ T cells by a four-component DNA-MVA/HIVA-RENTA candidate HIV-1 vaccine in rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Multiprotein genetic vaccine in the SIV-Macaca animal model: a promising approach to generate sterilizing immunity to HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

GTU-MultiHIV DNA vaccine results in protection in a novel P815 tumor challenge model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Improved protection against simian immunodeficiency virus mucosal challenge in macaques primed with a DNA vaccine and boosted with the recombinant modified vaccinia virus Ankara and recombinant Semliki Forest virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Comparative ability of various plasmid-based cytokines and chemokines to adjuvant the activity of HIV plasmid DNA vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Efficacy of DNA and fowlpox virus priming/boosting vaccines for simian/human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Genetic vaccination strategies for enhanced cellular, humoral and mucosal immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Red blood cell-mediated delivery of recombinant HIV-1 Tat protein in mice induces anti-Tat neutralizing antibodies and CTL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Expression of human immunodeficiency virus type 1 tat from a replication-deficient herpes simplex type 1 vector induces antigen-specific T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Reconstruction and Function of Ancestral Center-of-Tree Human Immunodeficiency Virus Type 1 Proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

The therapeutic phase I trial of the recombinant native HIV-1 Tat protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

Evaluation in macaques of HIV-1 DNA vaccines containing primate CpG motifs and fowlpoxvirus vaccines co-expressing IFN? or IL-12

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180903013026

10.1080/08830180903013026

21 January 2018

Identifiers

DOI

1 reference

21 June 2017

1 reference